Kles Keri A, Bril Vera
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.
Curr Diabetes Rev. 2006 Aug;2(3):353-61. doi: 10.2174/157339906777950598.
Diabetes and its complications are major causes of mortality in the United States, with increasing rates of morbidity and increasing health care costs. Patients diagnosed with diabetes attempt to control cholesterol levels, blood pressure, and blood glucose levels to decrease the risk of diabetic microvascular complications (DMC), such as diabetic sensorimotor polyneuropathy (DSP) [also known as diabetic peripheral neuropathy (DPN)]. Despite control of these risk factors for vascular disease, many patients still develop DSP. Research investigating diabetic neuropathy holds promise for specific treatment of diabetic complications. Intrinsic to the success of new therapies is the accurate diagnosis and evaluation of DSP. Symptom scores, quantitative sensory testing and electrophysiology are some of the diagnostic tools to identify the signs and symptoms of DSP. Early detection of neuropathy enables clinicians to prevent long-term complications like ulcers and amputations in patients with diabetes. The focus of this review is to describe the composite of tools necessary for diagnosis of DSP.
糖尿病及其并发症是美国主要的死亡原因，发病率不断上升，医疗保健成本也在增加。被诊断为糖尿病的患者试图控制胆固醇水平、血压和血糖水平，以降低糖尿病微血管并发症（DMC）的风险，如糖尿病感觉运动性多发性神经病变（DSP）[也称为糖尿病周围神经病变（DPN）]。尽管对这些血管疾病风险因素进行了控制，但许多患者仍会发生DSP。研究糖尿病神经病变有望实现对糖尿病并发症的特异性治疗。新疗法成功的关键在于对DSP进行准确的诊断和评估。症状评分、定量感觉测试和电生理学是识别DSP体征和症状的一些诊断工具。早期发现神经病变可使临床医生预防糖尿病患者出现溃疡和截肢等长期并发症。本综述的重点是描述诊断DSP所需的综合工具。
